Media Advisory: Public Session of the Cancer Drug Development Roundtable at Ohio State

April 25, 2011

WHAT: Public Session of the Cancer Drug Development Roundtable at Ohio State

The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) and Friends of Cancer Research (Friends) are convening a high-level group of stakeholders to discuss current obstacles halting co-development of two or more experimental drugs for the treatment of cancer.

In December 2010, the U.S. Food and Drug Administration (FDA) released a Guidance Document addressing the protocol researchers should follow when deciding if co-developing drugs is appropriate. However, barriers found outside of clinics and labs, such as business, legal, liability and intellectual property issues were not examined in detail.

The objective of the Cancer Drug Development Roundtable is to develop a set of recommendations for the FDA to be revealed later this year, addressing industry hurdles currently halting co-development, with the ultimate goal of easing the process and bringing revolutionary cancer treatments to patients faster and with more efficiency.

Prior to the closed working session occurring later in the day, Roundtable participants will hold an open public session for researchers, advocates, patients and media that would like to learn more about the issue and ask questions. Panel participants include:

  • Michael Caligiuri, M.D. - Director of The Ohio State Comprehensive Cancer Center and CEO of the James Cancer Hospital and Solove Research Institute
  • Jim Doroshow, M.D. - Director of the Division of Cancer Treatment and Diagnosis at the National Cancer Institute
  • Eric Rubin, M.D. - Vice President, Oncology Clinical Research, Merck
  • Ellen Sigal, Ph.D. - Chair and Founder, Friends of Cancer Research
  • Janet Woodcock, M.D. - Director, Center for Drug Evaluation and Research, FDA

WHERE: The Ohio State University, Biomedical Research Tower, Room 115, 460 W. 12th Avenue, Columbus, OH 43210

For those unable to attend in person, the Public Session will also be made available via Webcast and teleconference (Please RSVP to lbryan@spectrumscience.com for dial-in information and link).

WHEN: Wednesday, May 4, 2011

10:00 – 11:00 a.m.

WHO: Hosted by Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) and Friends of Cancer Research (Friends)

# # #

Eileen Scahill
Medical Center Public Affairs and Media Relations
614-293-3737
Eileen.Scahill@osumc.edu

Contact Media Staff

Amanda Harper

Director of Media Relations


614-685-5420 (direct)


614-293-3737 (main)


Amanda.Harper2@osumc.edu


Media staff are available by calling 614-293-3737 Monday through Friday between 8 a.m. and 5 p.m.

 

If after hours, please call 614-293-8000 (ask the operator to page the hospital administrative manager).

Latest News

James Experts Find that Yoga Reduces Fatigue and Inflammation for Breast Cancer Survivors

Experts at The James found in a recent study that practicing yoga for as little as just three months can actually help reduce fatigue and lower inflammation in breast cancer survivors.

The I Ride for You Program Gives Purpose to a Cancer Diagnosis

Jamine Waggle, Cancer Survivor and I Ride for You participant, shares how Pelotonia and the I Ride for You program helped her find purpose in her cancer diagnosis.

The Statue of Hope Dedication at the New James

The Statue of Hope, a symbol of hope and inspiration for patients, medical experts and visitors to The James, received a formal welcome and dedication this week in front of the new James Cancer Hospital.